about
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous miceDiscovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancerSMG-1 and mTORC1 act antagonistically to regulate response to injury and growth in planariansStructural Basis for the Association of the Redox-sensitive Target of Rapamycin FATC Domain with Membrane-mimetic MicellesBiomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further ProposalsOsteopontin is Critical for Hyperactive mTOR-Induced Tumorigenesis in Oral Squamous Cell CarcinomaThe combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivitySuppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.Increased activation of the PI3K/AKT pathway compromises decidualization of stromal cells from endometriosis.Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.Diacylglycerol kinase-ζ regulates mTORC1 and lipogenic metabolism in cancer cells through SREBP-1A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation.Characterization of pomiferin triacetate as a novel mTOR and translation inhibitormTOR's role in ageing: protein synthesis or autophagy?Targeting translation dependence in cancerClinical activity of mammalian target of rapamycin inhibitors in solid tumors.Research and innovation in the development of everolimus for oncology.A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells.Intact neuronal function in Rheb1 mutant mice: implications for TORC1-based treatments.Repeated systemic treatment with rapamycin affects behavior and amygdala protein expression in rats.S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt.Preclinical evidence of the enhanced effectiveness of combined rapamycin and AICAR in reducing kidney cancermTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential
P2860
Q24597354-C89A9B58-92F9-4E4A-839A-CB73CF50BF02Q24617184-59E9B315-57D2-4CD5-AD91-AAEDC243410EQ27334311-3A945128-6791-44B8-80FD-E3FD02DE06C2Q27658819-E4D15970-97EE-433C-BA9C-D3E1EC8FE8D3Q33760578-012A8364-702B-4AC9-B441-EB379F98E8C9Q33820845-D0D3BFA9-DF80-4F3F-BE4D-B66CEC246DA5Q34036041-0B643954-1AB2-4955-93DD-22A63A1D4FA6Q34466060-D8AC3CA4-EDA5-4F0A-80D9-358E927AA225Q34600369-19535555-7963-4CD3-A104-EF03EA6FA956Q35176904-429EEDC4-3933-4DDC-8CE4-5B4DBA67F7D1Q35374899-B6A821D8-57E5-4710-A1C7-70B12AF14CFCQ35654201-2CCBFA60-1FA4-47E9-AD29-8EFC10A2D58BQ35879915-E6F0B19D-D412-400D-B9B9-45D79481C0CDQ35885030-17FADA4E-CA79-485F-9EC5-30358AF38E08Q36098645-9570B16F-6BEA-40EB-A822-B1D38B6493AEQ36245893-483851F3-CD34-48DB-B085-6CB973BCBEEAQ36502058-428EE216-D008-4B81-8EC6-67FB3D63AE34Q37689248-E86E660C-0E71-4789-BD52-56E4FA3CDF80Q37693034-01A7DFCC-A271-458D-9703-DF864133CFF0Q37850227-01332D1B-A336-4370-8C83-FFE2D1E2411BQ37871915-76764AC0-57A0-4F3E-9486-6E932B447373Q38014589-73CB56B1-0342-422B-BE8E-68A7BFC94447Q38083828-E9B28B6C-400B-4372-95F8-334DD4DFF137Q38494344-77D23721-AB87-41F6-9B7A-71A4D9E61188Q42730006-2E1D95E2-F194-4E1C-BB82-6AB9D34111A4Q42906858-722CC7B4-7C3C-4D7C-AABE-025D3B290835Q47585107-9BCEEDF8-7121-4094-A0FA-B36F81D4EB0DQ48286797-D5CCBDE7-5F78-46F5-87BE-AE53DB0DADACQ50105351-1AAFEBA7-CF5B-4830-84AF-2E1E62EC5FFFQ54561835-415FC686-3BC4-4B19-A5A4-DF33FD43F160Q58738564-307D8D2B-CFC3-4AF8-8AD0-D30DBB16DC49Q59130211-4A063EB0-1F69-4F5F-80D7-7D7C0BF9E790
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimal targeting of the mTORC1 kinase in human cancer.
@en
Optimal targeting of the mTORC1 kinase in human cancer.
@nl
type
label
Optimal targeting of the mTORC1 kinase in human cancer.
@en
Optimal targeting of the mTORC1 kinase in human cancer.
@nl
prefLabel
Optimal targeting of the mTORC1 kinase in human cancer.
@en
Optimal targeting of the mTORC1 kinase in human cancer.
@nl
P1476
Optimal targeting of the mTORC1 kinase in human cancer.
@en
P2093
Heidi A Lane
Madlaina Breuleux
P304
P356
10.1016/J.CEB.2009.01.016
P577
2009-02-21T00:00:00Z